Patents Assigned to CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)
-
Publication number: 20240287454Abstract: The present invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, at least 20% are CD27/CD28 double positive and less than 10% are triple positive for CD45RA, CD57 and KLRG1 and a method for expansion of a population of lymphocytes specific for one or more antigens comprising a single culture phase.Type: ApplicationFiled: April 29, 2022Publication date: August 29, 2024Applicants: TIGEN PHARMA SA, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventors: George Coukos, Alexandre Harari, Simone Steiner, Florence Salmon
-
Publication number: 20240225687Abstract: The invention relates to a surgical device to be used in orthopaedic treatment. In particular, the present invention relates to a surgical system for minimally invasive treatment of a trigger finger.Type: ApplicationFiled: February 16, 2022Publication date: July 11, 2024Applicant: Centre Hospitalier Universitaire Vaudois (CHUV)Inventors: Debora Schivo, Sebastien Durand, Didier Maillefer, Severino Tehrani
-
Publication number: 20240130758Abstract: The invention relates to a surgical device to be used in orthopaedic treatment. In particular, the present invention relates to a surgical system for minimally invasive treatment of a trigger finger.Type: ApplicationFiled: February 16, 2022Publication date: April 25, 2024Applicant: Centre Hospitalier Universitaire Vaudois (CHUV)Inventors: Debora Schivo, Sebastien Durand, Didier Maillefer, Severino Tehrani
-
Patent number: 10751416Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.Type: GrantFiled: July 13, 2016Date of Patent: August 25, 2020Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller
-
Publication number: 20180207271Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.Type: ApplicationFiled: July 13, 2016Publication date: July 26, 2018Applicants: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Michel GILLIET, Jeremy DI DOMIZIO, Stephan MELLER
-
Publication number: 20170224843Abstract: A treatment of Huntington's disease (HD) using the Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR) system. This technology offers the possibility to design a small RNA (sgRNA), which is incorporated into a CRISPR-associated protein (Cas9) to recognize and induce DNA double-strand breaks at a specific target location. In the context of HD, this allows to block the expression of the mutant huntingtin or repair the CAG expansion causing the disease.Type: ApplicationFiled: August 4, 2015Publication date: August 10, 2017Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventors: Nicole DEGLON, Nicolas MERIENNE
-
Patent number: 9434923Abstract: The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair.Type: GrantFiled: February 12, 2015Date of Patent: September 6, 2016Assignee: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventor: Lee Ann Laurent-Applegate
-
Patent number: 8703444Abstract: The present invention relates to micro-organisms and to methods of producing proteins. More specifically, the inventions relates to a host cell useful for the expression of heterozygous proteins in which the host cell, Pichia pastoris, has been genetically modified so that the gene for endogenous secreted subtilisin Sub2 protease is completely or partially inactivated.Type: GrantFiled: December 13, 2010Date of Patent: April 22, 2014Assignee: Centre Hospitalier Universitaire Vaudois (CHUV)Inventor: Michel Monod
-
Publication number: 20120295307Abstract: The present invention relates to micro-organisms and to methods of producing proteins. More specifically, the inventions relates to a host cell useful for the expression of heterozygous proteins in which the host cell, Pichia pastoris, has been genetically modified so that the gene for endogenous secreted subtilisin Sub2 protease is completely or partially inactivated.Type: ApplicationFiled: December 13, 2010Publication date: November 22, 2012Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventor: Michel Monod
-
Publication number: 20120276075Abstract: The present invention relates to a novel enzyme composition comprising a prolyl protease and tripeptidyl proteases having unique catalytic properties. The present invention further relates to methods for producing the enzyme composition as well as a pharmaceutical composition and a food supplement containing the enzyme composition and its use in the degradation of polypeptides.Type: ApplicationFiled: December 20, 2010Publication date: November 1, 2012Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)Inventors: Michel Monod, Eric Grouzmann